Biotech Values

[DewDiligence]

European Patent Office backs Teva’s Copaxone patent that runs until 2025:

http://www.sec.gov/Archives/edgar/data/818686/000130901414000369/exhibit1.htm

This has no material effect on MNTA insofar as the NVS/MNTA collaboration was not planning to develop a Copaxone FoB for the EU.

Three adversaries were cited in Teva’s PR: Synthon, MYL, and an unidentified party. The EPO decision most directly affects Synthon insofar as the EU was the main target market for Synthon’s Copaxone knockoff (#msg-99563993).